Your browser is no longer supported. Please, upgrade your browser.
Settings
CCXI ChemoCentryx, Inc. daily Stock Chart
CCXI [NASD]
ChemoCentryx, Inc.
Index- P/E- EPS (ttm)-1.10 Insider Own4.30% Shs Outstand61.30M Perf Week5.13%
Market Cap3.86B Forward P/E- EPS next Y-1.34 Insider Trans-44.53% Shs Float49.76M Perf Month-5.87%
Income-65.20M PEG- EPS next Q-0.34 Inst Own70.90% Short Float9.98% Perf Quarter2.98%
Sales33.80M P/S114.07 EPS this Y-28.00% Inst Trans7.81% Short Ratio6.81 Perf Half Y17.37%
Book/sh0.98 P/B56.48 EPS next Y5.60% ROA-30.70% Target Price73.00 Perf Year704.51%
Cash/sh2.64 P/C20.99 EPS next 5Y- ROE-100.50% 52W Range6.16 - 65.43 Perf YTD39.95%
Dividend- P/FCF- EPS past 5Y2.10% ROI-68.00% 52W High-15.41% Beta1.96
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin- 52W Low798.54% ATR2.72
Employees82 Current Ratio3.20 Sales Q/Q-27.70% Oper. Margin- RSI (14)48.24 Volatility5.22% 4.99%
OptionableYes Debt/Eq0.40 EPS Q/Q-55.10% Profit Margin- Rel Volume0.69 Prev Close55.35
ShortableYes LT Debt/Eq0.40 EarningsMay 11 AMC Payout- Avg Volume729.34K Price55.35
Recom1.50 SMA20-0.14% SMA50-4.52% SMA20030.48% Volume0 Change0.00%
Jun-17-20Initiated BTIG Research Buy $70
May-27-20Initiated Wells Fargo Overweight $79
May-12-20Reiterated H.C. Wainwright Buy $60 → $69
Jan-24-20Reiterated H.C. Wainwright Buy $40 → $60
Nov-26-19Reiterated Piper Jaffray Overweight $17 → $54
Nov-26-19Reiterated H.C. Wainwright Buy $23 → $40
Mar-27-19Upgrade B. Riley FBR Neutral → Buy $12.50 → $22
Feb-11-19Initiated Piper Jaffray Overweight $20
Sep-07-18Initiated B. Riley FBR Neutral $12.50
Aug-14-18Downgrade JP Morgan Overweight → Neutral
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Initiated H.C. Wainwright Buy $20
Feb-21-17Initiated JMP Securities Mkt Outperform
May-18-15Upgrade JP Morgan Neutral → Overweight
May-20-13Reiterated Stifel Buy $16 → $20
Nov-14-12Initiated Stifel Nicolaus Buy $16
Aug-04-20 08:30AM  
Aug-03-20 08:30AM  
Jul-27-20 12:31PM  
Jul-21-20 06:37AM  
Jul-17-20 11:02AM  
Jul-13-20 10:43AM  
Jul-10-20 11:11AM  
Jul-09-20 08:30AM  
Jul-07-20 11:14AM  
08:50AM  
Jun-29-20 12:53PM  
Jun-24-20 08:30AM  
Jun-15-20 10:34PM  
04:05PM  
Jun-12-20 09:49AM  
Jun-10-20 09:33PM  
04:08PM  
Jun-03-20 07:30AM  
May-18-20 08:30AM  
May-16-20 10:49AM  
May-14-20 06:53AM  
May-12-20 01:30PM  
May-11-20 07:55PM  
04:05PM  
07:00AM  
May-04-20 08:30AM  
Apr-27-20 12:31PM  
Apr-22-20 12:00PM  
Apr-07-20 12:00PM  
Apr-05-20 01:17AM  
Mar-31-20 04:52PM  
Mar-16-20 09:47AM  
Mar-12-20 07:00AM  
Mar-10-20 05:25PM  
04:05PM  
03:00PM  
Mar-03-20 08:30AM  
Mar-02-20 12:30PM  
Feb-19-20 08:30AM  
Jan-10-20 06:00PM  
05:01AM  
Jan-09-20 08:30AM  
Jan-08-20 08:30AM  
Dec-11-19 03:58PM  
Dec-01-19 09:30AM  
Nov-29-19 11:24AM  
Nov-28-19 09:00AM  
Nov-27-19 10:15AM  
10:09AM  
08:52AM  
07:26AM  
07:23AM  
Nov-26-19 02:03PM  
10:07AM  
08:42AM  
08:30AM  
08:14AM  
08:06AM  
07:00AM  
01:00AM  
01:00AM  
Nov-25-19 06:11PM  
04:05PM  
08:54AM  
Nov-20-19 05:32PM  
Nov-17-19 02:41AM  
Nov-11-19 08:33AM  
Nov-05-19 08:30AM  
Nov-04-19 06:45PM  
04:05PM  
Oct-30-19 06:59PM  
Oct-28-19 08:30AM  
Sep-24-19 08:30AM  
Aug-29-19 08:30AM  
Aug-17-19 06:09AM  
Aug-08-19 10:19AM  
Aug-05-19 07:25PM  
04:05PM  
Aug-02-19 05:48PM  
Aug-01-19 08:30AM  
Jul-31-19 08:30AM  
Jun-11-19 08:30AM  
Jun-06-19 07:37AM  
May-20-19 09:00AM  
May-11-19 02:05PM  
May-09-19 11:07AM  
May-07-19 01:29AM  
May-06-19 06:15PM  
05:12PM  
04:05PM  
Apr-29-19 08:30AM  
Apr-02-19 08:30AM  
Mar-28-19 08:30AM  
Mar-19-19 08:41AM  
Mar-18-19 10:04AM  
Mar-12-19 01:28AM  
Mar-11-19 05:30PM  
04:26PM  
04:05PM  
Mar-04-19 08:30AM  
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vifor (International) Ltd10% OwnerAug 03Sale53.9349,2582,656,6559,194,085Aug 03 07:10 PM
Vifor (International) Ltd10% OwnerJul 31Sale52.3940,4022,116,8259,243,343Aug 03 07:10 PM
Vifor (International) Ltd10% OwnerJul 30Sale54.6048,0812,625,3309,283,745Aug 03 07:10 PM
Vifor (International) Ltd10% OwnerJul 29Sale52.5888,0124,627,4799,331,826Jul 29 07:55 PM
Vifor (International) Ltd10% OwnerJul 28Sale53.5140,1602,149,1179,419,838Jul 29 07:55 PM
Vifor (International) Ltd10% OwnerJul 27Sale53.3234,2361,825,4769,459,998Jul 29 07:55 PM
Vifor (International) Ltd10% OwnerJul 24Sale52.5426,0501,368,7379,494,234Jul 24 07:53 PM
Vifor (International) Ltd10% OwnerJul 23Sale54.1534,5551,871,2979,520,284Jul 24 07:53 PM
Vifor (International) Ltd10% OwnerJul 22Sale55.5872,4694,027,8689,554,839Jul 24 07:53 PM
Vifor (International) Ltd10% OwnerJul 21Sale55.5087,5294,857,6329,627,308Jul 21 06:32 PM
Vifor (International) Ltd10% OwnerJul 20Sale56.0354,5983,059,0539,714,837Jul 21 06:32 PM
Vifor (International) Ltd10% OwnerJul 17Sale55.8647,8902,675,1059,769,435Jul 21 06:32 PM
Vifor (International) Ltd10% OwnerJul 16Sale56.9673,5004,186,7419,817,325Jul 16 08:00 PM
Vifor (International) Ltd10% OwnerJul 15Sale59.2286,2985,110,9719,890,825Jul 16 08:00 PM
Vifor (International) Ltd10% OwnerJul 14Sale58.08100,0005,808,3189,977,123Jul 16 08:00 PM
Vifor (International) Ltd10% OwnerJul 13Sale58.15100,0005,815,02710,077,123Jul 13 07:18 PM
Vifor (International) Ltd10% OwnerJul 10Sale59.9245,8442,747,17210,177,123Jul 13 07:18 PM
Vifor (International) Ltd10% OwnerJul 09Sale59.91100,0005,990,52110,222,967Jul 13 07:18 PM
Vifor (International) Ltd10% OwnerJul 08Sale59.95100,0005,994,74510,322,967Jul 08 08:39 PM
Vifor (International) Ltd10% OwnerJul 07Sale59.2179,3874,700,83810,422,967Jul 08 08:39 PM
Vifor (International) Ltd10% OwnerJul 06Sale58.4486,6905,066,12010,502,354Jul 08 08:39 PM
Vifor (International) Ltd10% OwnerJul 02Sale57.4787,7815,044,43410,589,044Jul 07 06:57 PM
Schall Thomas J.President and CEOJun 15Option Exercise14.312,00028,6202,270,557Jun 16 08:20 PM
Schall Thomas J.President and CEOJun 15Sale65.042,000130,0902,268,557Jun 16 08:20 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJun 12Option Exercise10.8633,541364,255109,788Jun 16 08:02 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 12Option Exercise9.3250,000466,100141,317Jun 16 08:08 PM
Schall Thomas J.President and CEOJun 12Option Exercise14.3188,7531,270,0552,357,310Jun 16 08:20 PM
Schall Thomas J.President and CEOJun 12Sale65.0888,7535,775,8772,268,557Jun 16 08:20 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 12Sale64.5850,0003,229,03591,317Jun 16 08:08 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJun 12Sale65.1033,5412,183,51976,247Jun 16 08:02 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 03Option Exercise5.3110,75057,059104,930Jun 05 07:11 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 26Option Exercise6.6219,612129,83195,859May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 26Sale60.3419,6121,183,42376,247May 26 09:04 PM
Tyree James LDirectorMay 23Option Exercise0.007,724013,069May 26 08:59 PM
Parker Geoffrey M.DirectorMay 23Option Exercise0.007,7240111,913May 26 08:55 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 22Option Exercise6.6240,867270,540117,114May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 22Sale60.0640,8672,454,52576,247May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 21Option Exercise6.622,80018,53679,047May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 21Sale60.002,800167,98676,247May 26 09:04 PM
Schall Thomas J.President and CEOMay 12Option Exercise14.3135,865513,2282,304,422May 12 07:50 PM
Schall Thomas J.President and CEOMay 12Sale57.7535,8652,071,1002,268,557May 12 07:50 PM
Schall Thomas J.President and CEOMay 11Option Exercise14.3170,6081,010,4002,339,165May 12 07:50 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 11Option Exercise3.5734,222122,173110,469May 12 07:45 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 11Sale55.1134,2221,886,13576,247May 12 07:45 PM
Schall Thomas J.President and CEOMay 11Sale55.5170,6083,919,7312,268,557May 12 07:50 PM
Schall Thomas J.President and CEOMay 08Option Exercise14.314,20160,1162,272,758May 12 07:50 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 08Option Exercise3.574,31215,39480,559May 12 07:45 PM
Schall Thomas J.President and CEOMay 08Sale55.014,201231,1152,268,557May 12 07:50 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 08Sale50.014,312215,63976,247May 12 07:45 PM
Schall Thomas J.President and CEOMay 05Option Exercise14.318,851126,6582,277,408May 07 08:11 PM
KANAYA SUSAN MEVP, CFO and Sec.May 05Option Exercise8.1920,123164,807111,440May 06 08:19 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 05Option Exercise3.578,86031,63085,107May 07 07:59 PM
Schall Thomas J.President and CEOMay 05Sale55.018,851486,8512,268,557May 07 08:11 PM
KANAYA SUSAN MEVP, CFO and Sec.May 05Sale54.7320,1231,101,23791,317May 06 08:19 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 05Sale55.018,860487,34576,247May 07 07:59 PM
KANAYA SUSAN MEVP, CFO and Sec.May 04Option Exercise8.1954,877449,443146,194May 06 08:19 PM
KANAYA SUSAN MEVP, CFO and Sec.May 04Sale54.5754,8772,994,81991,317May 06 08:19 PM
Jain RitaDirectorMar 27Option Exercise0.005,251012,975Mar 31 07:10 PM
Parker Geoffrey M.DirectorMar 23Sale36.7030,0001,101,04949,600Mar 25 06:42 PM
Schall Thomas J.President and CEOMar 04Option Exercise14.3140,844584,4782,309,401Mar 05 07:03 PM
Schall Thomas J.President and CEOMar 04Sale50.3540,8442,056,6912,268,557Mar 05 07:03 PM
Schall Thomas J.President and CEOFeb 20Option Exercise14.3115,341219,5302,283,898Feb 21 07:24 PM
Schall Thomas J.President and CEOFeb 20Sale50.2115,341770,2962,268,557Feb 21 07:24 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 19Option Exercise10.8624,200262,812118,380Feb 21 07:15 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 19Option Exercise8.1942,631349,148118,878Feb 21 07:05 PM
Schall Thomas J.President and CEOFeb 19Option Exercise14.3163,340906,3952,331,897Feb 21 07:24 PM
Schall Thomas J.President and CEOFeb 19Sale50.5063,3403,198,5142,268,557Feb 21 07:24 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 19Sale50.1324,2001,213,22194,180Feb 21 07:15 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 19Sale50.3642,6312,146,69876,247Feb 21 07:05 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 13Option Exercise9.7645,300442,029139,480Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 13Sale49.6145,3002,247,14794,180Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 12Option Exercise9.692,50024,21396,680Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 12Sale49.512,500123,77694,180Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 11Option Exercise10.683,00032,04697,180Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 11Sale49.503,000148,51094,180Feb 13 08:00 PM
Kwan Pui SanPrincipal Acctg OfficerFeb 11Sale49.1518,941930,888493Feb 13 07:50 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 06Option Exercise8.1936,850301,802113,097Feb 10 07:53 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 06Sale47.3136,8501,743,34076,247Feb 10 07:53 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 05Option Exercise8.1913,150107,69989,397Feb 05 08:02 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 05Sale47.0313,150618,45176,427Feb 05 08:02 PM
Schall Thomas J.President and CEOFeb 04Option Exercise14.31119,5251,710,4032,388,082Feb 06 06:51 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 04Option Exercise14.3199,6171,425,519193,797Feb 05 08:32 PM
Schall Thomas J.President and CEOFeb 04Sale45.18119,5255,400,7012,268,557Feb 06 06:51 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 04Sale45.1099,6174,492,22994,180Feb 05 08:32 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 03Option Exercise8.1948,471396,977124,718Feb 05 08:02 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 03Option Exercise14.313,83754,90798,017Feb 05 08:32 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 03Sale44.4748,4712,155,52576,247Feb 05 08:02 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 03Sale44.913,837172,31794,180Feb 05 08:32 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 21Option Exercise8.191,25910,31177,506Jan 23 07:31 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 21Sale44.001,25955,39276,247Jan 23 07:31 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 17Option Exercise14.2815,737224,724109,917Jan 17 07:49 PM
Schall Thomas J.President and CEOJan 17Option Exercise10.27105,7351,085,8982,374,292Jan 17 07:55 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 17Sale41.0315,737645,73094,180Jan 17 07:49 PM
Schall Thomas J.President and CEOJan 17Sale41.60105,7354,398,2722,268,557Jan 17 07:55 PM
Kwan Pui SanPrincipal Acctg OfficerJan 16Option Exercise8.3189,179740,881108,613Jan 17 07:36 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 16Option Exercise7.1050,000355,000126,247Jan 17 07:42 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 16Option Exercise14.2847,261674,887141,441Jan 17 07:49 PM
Schall Thomas J.President and CEOJan 16Option Exercise10.2730,317311,3562,298,874Jan 17 07:55 PM
Kwan Pui SanPrincipal Acctg OfficerJan 16Sale39.9189,1793,559,21619,434Jan 17 07:36 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 16Sale40.0750,0002,003,48076,247Jan 17 07:42 PM